Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationThe Phase 3 Randomized Clinical ClarIDHy Trial
https://jamanetwork.com/journals/jamaoncology/fullarticle/2784216?guestAccessKey=f3fb4658-7f77-4938-b7ab-290098644c4b&utm_source=twitter&utm_medium=social_jamaonc&utm_term=5933211983&utm_campaign=article_alert&linkId=140680185
“This randomized clinical trial found that ivosidenib was well tolerated and resulted in a favorable OS benefit vs placebo, despite a high rate of crossover. These data, coupled with supportive quality of life data and a tolerable safety profile, demonstrate the clinical benefit of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation.”
This is the trial info here – https://clinicaltrials.gov/ct2/show/NCT02989857
Thanks to The American Medical Association for this piece.
Gavin